{"schema_version":"secwatch.filing_event.v1","accession":"0001680367-24-000050","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.206341+00:00","generated_at":"2026-05-30T00:30:41.008950+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Shattuck Labs Q3 net loss $16.7M; shifts focus to SL-325 DR3 antibody; cash runway into 2027","bullets":["Net loss of $16.7M ($0.33 per share) vs $27.5M in Q3 2023; no revenue (pre-revenue stage).","Strategic pivot: discontinuing SL-172154; prioritizing first-in-class DR3 antagonist SL-325 with IND filing expected Q3 2025.","Cash and investments ~$90.1M as of Sept 30, 2024, expected to fund operations into 2027.","Substantially completed restructuring (workforce reduction) tied to SL-172154 discontinuation.","R&D expenses fell to $16.3M from $24.2M; G&A expenses dropped to $4.6M from $5.1M YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001680367-24-000050","json":"https://secwatch.observer/filing/0001680367-24-000050.json","markdown":"https://secwatch.observer/filing/0001680367-24-000050.md","text":"https://secwatch.observer/filing/0001680367-24-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000168036724000050/0001680367-24-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000168036724000050/sttk-20241114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:30:41.008950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}